Anti-CC9orf89抗体C9orf89 plays a role in inhibiting the effects of BCL10-induced activation of NF-kappa-B. It may inhibit the phosphorylation of BCL10 in a CARD-dependent manner. There are two isoforms.

产品编号 byb-15346R
英文名称 Anti-CC9orf89抗体
中文名称 9号染色体开放阅读框89抗体
别    名 Bcl10 interacting protein with CARD protein; BinCARD; Chromosome 9 open reading frame 89; BINCA_HUMAN.
 Anti-CC9orf89抗体
说 明 书 0.2ml  
研究领域 细胞生物  免疫学  
抗体来源 Rabbit
克隆类型 Polyclonal
交叉反应 Human, 
产品应用 WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 （石蜡切片需做抗原修复） 
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量 26kDa
细胞定位 细胞核 
性    状 Lyophilized or Liquid
浓    度 1mg/1ml
免 疫 原 KLH conjugated synthetic peptide derived from human C9orf89
亚    型 IgG
纯化方法 affinity purified by Protein A
储 存 液 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存条件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
 
PubMed PubMed
产品介绍 background:
C9orf89 plays a role in inhibiting the effects of BCL10-induced activation of NF-kappa-B. It may inhibit the phosphorylation of BCL10 in a CARD-dependent manner. There are two isoforms.

Function:
Plays a role in inhibiting the effects of BCL10-induced activation of NF-kappa-B. May inhibit the phosphorylation of BCL10 in a CARD-dependent manner.

Subunit:
Associates with BCL10 by CARD-CARD interaction.

Subcellular Location:
Nucleus. Note=Co-expression with BCL10 induced translocation from nucleus to cytosol. 

Tissue Specificity:
Expressed in ovary, testis, placenta, skeletal muscle, kidney, lung, heart and liver (at protein level). Expressed in thymus and brain.
 
Post-translational modifications:
Isoform 2 is phosphorylated upon DNA damage, probably by ATM or ATR.